Mark Kidd
Yale University
CancerInternal medicineEndocrinologyPathologyOncologyReceptorEnterochromaffin-like cellSomatostatinHelicobacter pyloriGastrinNeuroendocrine tumorsDiseaseRadionuclide therapyCancer researchMedicineBiomarker (medicine)Chromogranin ABiologyEnterochromaffin cellGastroenterology
309Publications
66H-index
12.9kCitations
Publications 309
Newest
#1Anna Malczewska (Medical University of Silesia)H-Index: 12
#2Beata Kos-Kudła (Medical University of Silesia)H-Index: 31
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 8 authors...
Abstract Purpose There are few effective biomarkers for neuroendocrine tumors. Precision oncology strategies have provided liquid biopsies for real-time and tailored decision-making. This has led to the development of the first neuroendocrine tumor liquid biopsy (the NETest). The NETest represents a transcriptomic signature of neuroendocrine tumor (NETs) that captures tumor biology and disease activity. The data have direct clinical application in terms of identifying residual disease, disease p...
8 CitationsSource
#1Irvin M. Modlin (Yale University)H-Index: 81
#2Mark Kidd (Yale University)H-Index: 66
Last. Harry R. Aslanian (Yale University)H-Index: 28
view all 7 authors...
18Background: There are a paucity of blood-based biomarkers with clinical utility for colorectal cancer (CRC) We report the use of a 13-gene colon cancer circulating-free mRNA to diagnose CRC and i...
Source
#1Somer MatarH-Index: 7
#2Anna MalczewskaH-Index: 12
Last. Irvin M. ModlinH-Index: 81
view all 15 authors...
BACKGROUND: Identification of circulating tumor markers for clinical management in bronchopulmonary (BP) neuroendocrine tumors/neoplasms (NET/NEN) is of considerable clinical interest. Chromogranin A (CgA), a "universal" NET biomarker, is considered controversial as a circulating biomarker of BPNEN. AIM: Assess utility of CgA in the diagnosis and management of BPNEN in a multicentric study. MATERIAL AND METHODS: CgA diagnostic metrics were assessed in lung NET/NENs (n=200) and controls (n=140), ...
6 CitationsSource
#1Anna Malczewska (Medical University of Silesia)H-Index: 12
#2Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 4 authors...
Context: Early cancer detection is critical to optimize treatment. This is particularly problematic in neuroendocrine tumors (NETs), which exhibit an ∼5-year diagnostic delay due to covert symptoms, limitations in imaging, and circulating biomarkers. Despite development of continuous monitoring strategies utilizing advanced modalities [CT/MRI or 68Gallium positron emission tomography (PET)/CT] or a repertoire of monoanalyte biomarkers [e.g., chromogranin A (CgA), pancreastatin, serotonin], detec...
18 CitationsSource
#1Irvin M. ModlinH-Index: 81
#2Mark KiddH-Index: 66
Last. Kyung-Min ChungH-Index: 5
view all 7 authors...
Source
#1Irvin M. Modlin (Yale University)H-Index: 81
#2Mark KiddH-Index: 66
Last. Kyung-Min ChungH-Index: 5
view all 7 authors...
: The neuroendocrine neoplasms test (NETest) is a multianalyte liquid biopsy that measures neuroendocrine tumor gene expression in blood. This unique signature precisely defines the biological activity of an individual tumor in real time. The assay meets the 3 critical requirements of an optimal biomarker: diagnostic accuracy, prognostic value, and predictive therapeutic assessment. NETest performance metrics are sensitivity and specificity and in head-to-head comparison are 4-fold to 10-fold mo...
38 CitationsSource
#1Cansu Guney GencH-Index: 4
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 9 authors...
Background: Recurrence of pancreatic neuroendocrine tumors (pNET) after surgery is common. Strategies to detect recurrence have limitations. We investigated the role of clinical criteria and the multigene polymerase chain reaction–based NETest during post-operative follow-up of pNET. Methods: We studied 3 groups of resections: R0 with no recurrence (n = 11), R0 with recurrence (n = 12), and R1 with no recurrence (n = 12). NETest levels (>40%) were compared with chromogranin A (CgA) and clinicopa...
19 CitationsSource
#1Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
#2Mark Kidd (Yale University)H-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 12 authors...
4101Background: PRRT uses somatostatin receptor (SSR) expression on neuroendocrine tumors (NET) to deliver radiotherapy. Pretreatment patient stratification for response remains a key unmet need. NET transcript expression in blood integrated with tumor grade provides a PRRT predictive quotient (PPQ). This study validates the clinical utility for PRRT. Methods: Development and validation was undertaken in 3 independent 177Lu-PRRT-cohorts. Specificity and prognostic value was tested in two somatos...
1 CitationsSource
#1Pier Luigi Filosso (UNITO: University of Turin)H-Index: 38
#2Mark KiddH-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 24 authors...
OBJECTIVES: The management of bronchopulmonary neuroendocrine tumours (BPNETs) is difficult, since imaging, histology and biomarkers have a limited value in diagnosis, predicting outcome and defining therapeutic efficacy. We evaluated a NET multigene blood test (NETest) to diagnose BPNETs, assess disease status and evaluate surgical resection. METHODS: (i) Diagnostic cohort: BP carcinoids (n = 118)-typical carcinoid, n = 67 and atypical carcinoid, n = 51; other lung NEN (large-cell neuroendocrin...
25 CitationsSource
#1Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
#2Mark KiddH-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 12 authors...
Background Peptide receptor radionuclide therapy (PRRT) utilizes somatostatin receptor (SSR) overexpression on neuroendocrine tumors (NET) to deliver targeted radiotherapy. Intensity of uptake at imaging is considered related to efficacy but has low sensitivity. A pretreatment strategy to determine individual PRRT response remains a key unmet need. NET transcript expression in blood integrated with tumor grade provides a PRRT predictive quotient (PPQ) which stratifies PRRT “responders” from “non...
60 CitationsSource